While MEK1/2 inhibitors are used for clinical cancer therapy and have been assessed in MPN models [18, 19], inhibitors targeting ERK1/2 have just been developed recently and have not been explored in MPN settings. This evidence concerns the gene MAP2K1 and cancer.